Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China

Siyi Zhu1,2☯, Qiang Gao1,2☯, Lin Yang1,2☯, Yonghong Yang1,2☯, Wenguang Xia3, Xiguo Cai4, Yanping Hui5, Di Zhu6, Yanyan Zhang7, Guiqing Zhang8, Shuang Wu9, Yiliang Wang10, Zhiqiang Zhou11, Hongfei Liu12, Changjie Zhang13, Bo Zhang14, Jianrong Yang15, Mei Feng16, Zhong Ni16, Baoyu Chen1, Chunping Du1,2, Hongchen He1,2,17☯, Yun Qu1,2, Quan Wei1,2, Chengqi He1,2,17*, Jan D. Reinhardt17,18,19,20☯

1 Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu, China, 2 Rehabilitation Medicine Key Laboratory of Sichuan Province, Sichuan University, Chengdu, China, 3 Hubei Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, Hubei, China, 4 Henan Provincial People’s Hospital, Zhengzhou, Henan, China, 5 The Second Affiliated Hospital, Medical College of X’ian Jiaotong University, Xian, Shanxi, China, 6 Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang, China, 7 Qilu Hospital of Shandong University, Jinan, Shandong, China, 8 The First Affiliated Hospital, School of Medicine, Shihui University, Xinjiang, China, 9 The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China, 10 Chongqing Three Gorges Central Hospital, Chongqing, China, 11 Inner Mongolia Autonomous Region Baotou Central Hospital, Baotou, China, 12 General Hospital of General Bureau of Agricultural Reclamation of Heilongjiang Province, Harbin, China, 13 The Second Xiangya Hospital of Central South University, Changsha, China, 14 Nanchong Central Hospital, Nanchong, Sichuan, China, 15 Garze People’s Hospital, Garze Tibetan Autonomous Prefecture, Sichuan, China, 16 Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China, 17 Institute for Disaster Management and Reconstruction of Sichuan University and Hong Kong Polytechnic University, Sichuan University, Chengdu, China, 18 Swiss Paraplegic Research, Nottwil, Switzerland, 19 Department of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland, 20 Xidian Hospital Group, Xi’an, Shaanxi, China

* These authors contributed equally to this work.

Abstract

Objective
To estimate the prevalence of disability and anxiety in Covid-19 survivors at discharge from hospital and analyze relative risk by exposures.

Design
Multi-center retrospective cohort study.

Setting
Twenty-eight hospitals located in eight provinces of China.

Methods
A total of 432 survivors with laboratory-confirmed SARS CoV-2 infection participated in this study. At discharge, we assessed instrumental activities of daily living (IADL) with Lawton’s...
IADL scale, dependence in activities of daily living (ADL) with the Barthel Index, and anxiety with Zung’s self-reported anxiety scale. Exposures included comorbidity, smoking, setting (Hubei vs. others), disease severity, symptoms, and length of hospital stay. Other risk factors considered were age, gender, and ethnicity (Han vs. Tibetan).

**Results**

Prevalence of at least one IADL problem was 36.81% (95% CI: 32.39–41.46). ADL dependence was present in 16.44% (95% CI: 13.23–20.23) and 28.70% (95% CI: 24.63–33.15) were screened positive for clinical anxiety. Adjusted risk ratio (RR) of IADL limitations (RR 2.48, 95% CI: 1.80–3.40), ADL dependence (RR 2.07, 95% CI 1.15–3.76), and probable clinical anxiety (RR 2.53, 95% CI 1.69–3.79) were consistently elevated in survivors with severe Covid-19. Age was an additional independent risk factor for IADL limitations and ADL dependence; and setting (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a protective factor for anxiety but a risk factor for IADL limitations.

**Conclusion**

A significant proportion of Covid-19 survivors had disability and anxiety at discharge from hospital. Health systems need to be prepared for an additional burden resulting from rehabilitation needs of Covid-19 survivors.

**Introduction**

With rapidly increasing numbers of confirmed cases and deaths caused by the Coronavirus Disease-2019 (Covid-19) pandemic, clinical outcomes research has almost exclusively focused on disease progression and mortality [1]. With the case fatality rate estimated to lie somewhere between 0.56 and 9.38 percent globally (95% prediction interval, $I^2 = 100\%$) [2], it is obvious however that a vast majority of people actually survive Covid-19. A substantial proportion of survivors have experienced severe disease episodes requiring hospitalization and—in a considerable number of cases—intensive care including mechanical ventilation [3]. In addition, contracting a potentially fatal disease is stressful and can cause anxiety and other psychiatric manifestations in many patients [4]. It would be naïve to assume that health problems just disappear upon discharge from acute care or when viral RNA is no longer detectable, and equally naïve to take planned and systematic follow up of patients for granted [5, 6]. Yet, the burden of disease resulting from physical and psychological sequelae of Covid-19 in patients surviving the disease as well as potential long-term adverse effects from treatments including steroids such as Dexamethasone are just beginning to catch attention [7, 8].

Globally, respiratory infections and tuberculosis assume already the fourth rank of all diseases in terms of disability adjusted life years (DALYs) and the 17th rank in years lived with disability (YLD). In infectious disease, they sadly rank first and second, respectively [9, 10]. Covid-19 will increase this burden considerably and cause longer term mental and physical health problems, work disability, and reduced quality of life in survivors, frontline health professionals, and those quarantined [11, 12]. What we know from the 2002/2003 Severe Acute Respiratory Syndrome (SARS) epidemic is not encouraging. In Hong Kong for example, about 80 percent of SARS survivors still needed follow-up treatment two years after the outbreak had been contained [13].
The number of patients needing follow-up care and rehabilitation due to Covid-19 will be unprecedented. Countries need to consider and plan for this additional long-term challenge to the health system. It is important to understand risk factors for disability and mental health problems now in order to direct scarce resources and meet windows of opportunity for treatment. This study makes a first attempt to address this issue. We aimed to (1) estimate the prevalence of disability and anxiety in Covid-19 survivors from eight Provinces/centrally governed municipalities of the PR China at discharge from acute inpatient treatment, and (2) investigate relative risk of adverse outcomes by various determinants including gender, age, comorbidity, setting, ethnicity and disease severity. Prevalence estimates are important to gain insight in the potential number of patients needing follow-up care. Analyzing risk factors is instrumental in identifying vulnerable groups and allocating resources for early interventions.

Methods

Study design

We conducted a multi-center retrospective cohort study.

Ethics procedures

The study protocol was approved by the ethics committee of West China Hospital, Sichuan University (2020–163 and 2020–273). All participating health professionals were instructed on implementation of the study protocol, informed consent procedures, and possible sources of bias by videoconference. Patients were informed by the health professionals either face to face (if they were still hospitalized) or via telephone or WeChat call (if they had already been discharged) about the study purpose and content, and that participation was voluntary and could be withdrawn at any time. Informed consent was then obtained either in written form or verbally. Verbal informed consent was obtained if the patients were either illiterate or had already been discharged. Verbally provided informed consent was witnessed by a second health professional and recorded electronically. The data analyzed and contact information for the participants were strictly separated with the only link between them being a unique ID number without identifying information. Only Drs S Zhu and C He had access to both datasets.

Study participants

Four hundred and thirty-two Covid-19 survivors were surveyed who had received treatment in 28 designated hospitals in Hubei, Sichuan, Guizhou, Henan, Neimenggu (Inner Mongolia), Shandong, Hainan, and Chongqing with admission dates from January 18 to March 15, 2020 and gave informed consent. Included were adults (≥ 16 years) who had laboratory-confirmed SARS coronavirus-2 (SARS CoV-2) infection and met the diagnostic criteria of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) issued by the National Health Commission of the PR China (Third edition) [14]. Survivors further needed to be in stable medical condition and have been discharged or be about to be discharged from the participating centers. Excluded were patients with pneumonia caused by other types of coronaviruses, seasonal influenza, bacteria, or other not SARS CoV-2 etiology.

Measures

Data on outcomes and patient-reported exposures/risk factors was collected and informed consent was obtained between February 21 and April 7, 2020.

Outcomes. Outcomes were disability and anxiety. Cut off date for outcome assessment was April 7, 2020. Disability was measured in two ways: (1) Limitations in instrumental
activities of daily living (IADL) were assessed with the Lawton IADL scale [15] and classified into no limitations vs. one or more limitations with the latter indicating an unfavorable primary outcome. An index of the number of reported IADL limitations was also created. (2) Dependence in activities of daily living (ADL) was measured with the Barthel Index [16] and classified into severe or moderate dependence vs. mild dependence/independence with BI scores smaller than 75 indicating an unfavorable secondary outcome [17]. Anxiety was evaluated with Zung’s Self-Reported Anxiety Scale [18] (SAS) and classified into probable clinical anxiety disorder vs. not according to a conservative cutoff recommended for research with SAS scores of 40 or greater indicating an unfavorable secondary outcome [19]. Outcome data were patient-reported and collected with an online questionnaire.

Risk factors. Clinical and demographic data were extracted from hospital records by participating health professionals. Current smoking status was self-reported by participants. Demographic data included age, gender, province (Hubei vs. others), and ethnicity (Han vs. Tibetan). Having received treatment in Hubei was considered a risk factor because of the particular situation in Hubei which was the epicenter of the epidemic in China representing about 80 percent of confirmed cases. Ethnicity was included as a significant proportion of the Sichuan Province sample belonged to the Tibetan ethnic group, and belonging to a minority ethnic group is known to be associated with health outcomes in other disease. Clinical data included comorbidity, disease severity, symptoms at admission, scope of pneumonia, and length of inpatient stay. Recorded comorbid conditions included COPD, chronic bronchitis, pulmonary fibrosis, hypertension, diabetes, cardiovascular disease, kidney disease, hepatitis, rheumatism, and gout. Degree of Covid-19 severity was classified according to the Chinese standard [14]. Patients were defined as severe cases when they met one of the following criteria at any time during hospitalization: acute respiratory distress, respiratory rate ≥ 30 breath/min; pulse oxygen saturation (SpO2) ≤ 93% at rest; arterial blood partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring ICU treatment. Symptoms recorded at admission included fever, cough, diarrhea, fatigue and pain. Scope of pneumonia was noted as uni- or bilateral per radiographic findings. Data on length of hospital stay were available for 408 patients (94.44%).

Sample size calculation
Sample size to detect a two-fold relative risk for reporting an unfavorable primary outcome, i.e. one or more IADL limitations, in the severe disease group as compared to the non-severe group with a power of 80% and alpha error of 5% was estimated under the following assumptions: 0.2 ratio of severe to non-severe group (based on patients received at our own center), 15 percent prevalence of outcome in non-severe group. This yielded a minimal sample size of 401 (67 severe, 334 non-severe).

Analysis
Demographic and clinical characteristics of the sample are described by providing numbers of participants and percentages (categorical variables) or medians and inter-quartiles (continuous variables). Non-severe and severe cases are compared with regard to these characteristics with p-values for differences estimated from chi-squared tests (categorical variables) or Mann-Whitney U tests (continuous variables). Prevalence of limitations in IADL, ADL dependence, and anxiety for the full sample and by disease severity are provided with 95% confidence intervals (CIs) and p-values estimated from logistic regression. The strength of association between outcomes is reported as Cramer’s V with p-values from chi-squared tests. Cramer’s V ranges
from zero (no association) to one (perfect association) with values from 0.3 to 0.5 indicating moderate effects and values above 0.5 indicating large effects [20]. Risk ratios (RR) and 95% CIs for unfavorable outcomes (disability, anxiety) by gender, age group (< 50, 50–60, > 60 years), province (others vs. Hubei), ethnicity (Han vs. Tibetan), comorbid health conditions (none, one, multiple), disease severity (non-severe vs. severe), symptoms (< 1, > 1) at admission, and infection scope (unilateral vs. bilateral) were estimated with log-linear Poisson regression with robust standard errors [21]. Since longer time of being hospitalized could increase anxiety, length of hospital stay was included in the anxiety-model in addition. For each outcome unadjusted RR and RR adjusted for all other potential risk factors evaluated are provided. Zero-inflated Poisson (ZIP) regression was used to estimate the effect of risk factors on the extent of IADL limitations. ZIP regression assumes that there are two groups in the population from which the data are sampled, one which always has zero counts, and one which may have zero or higher counts. Young people with non-severe disease who have no comorbidity may never develop IADL limitations, while other groups may develop (additional) IADL limitations due to factors associated with disease progression. ZIP regression simultaneously performs logistic and Poisson regression making two types of predictions: (1) prediction of excess zeros assuming a binary dependent variable (no IADL limitations vs. one or more), (2) prediction of the count portion (number of experienced IADL limitations). Predictors included in the logistic part were the following background factors: age group and interaction of age and disease severity, province, ethnicity, smoking, and comorbid conditions. Predictors included in the count part were potential drivers of disease consequences: disease severity, interaction of age and disease severity, symptoms, and infection scope. Vuong’s test confirmed fit of the ZIP model.

All analyses were performed with Stata 14 (Stata corporation, Texas, USA).

Results

Sample description and prevalence of outcomes

Demographic and clinical characteristics and prevalence of outcomes of the study participants are provided in Table 1. Median age was 49 (IQR 35–60) and 49% were female. About one third of the study participants were classified as severe cases. Fever, cough, and fatigue were the most common symptoms at admission. A majority had no pre-existing health condition and were non-smokers. Patients with severe Covid-19 were older, were more often from Hubei and belonged to the Han majority, presented with more symptoms, had more often bilateral pneumonia, and stayed in the hospital for a longer time (all p < 0.001). More pre-existing health conditions were present in severe cases (p < 0.001), but the percentage of smokers was lower (p = 0.140). Over one third of Covid-19 survivors had at least one IADL limitation, about 15 percent had at least moderate ADL dependence, and six percent were severely dependent. Probable clinical anxiety disorder was found in about 29 percent of the population. Prevalence of all outcomes was more than four times higher in survivors of severe Covid-19 than in those with non-severe disease (all p < 0.001).

Associations between outcomes

Outcomes showed moderate to strong associations with Cramer’s V being 0.56 for the association between one or more IADL limitation and at least moderate dependence, 0.39 for the association between one or more IADL limitation and probable clinically relevant anxiety, and 0.33 for the association between at least moderate dependence and anxiety (all p < 0.001).
Table 1. Demographic and clinical characteristics of study participants (I) and prevalence of outcomes (II).

| I. Demographic and clinical characteristics | All participants (N = 432) | By disease severity |
|---------------------------------------------|---------------------------|---------------------|
|                                             |                           | non-severe          | severe              |
|                                             | (n = 285, 65.97%)         | (n = 147, 34.03%)   | P                   |
| Female sex–no./total no. (%)                | 207/432 (47.92)           | 138/285 (48.42)     | 69/147 (46.94)      | 0.770*                 |
| Age Median (IQR) in years                   | 49 (35–60)                | 45 (32.5–54.5)      | 57 (47–68)          | <0.001‡                |
| Distribution–no./total no. (%)              |                           |                     |                     | <0.001*                |
| < 50                                        | 218/431 (50.58)           | 173/284 (60.92)     | 45/147 (30.61)      |                       |
| 50–60                                       | 108/431 (25.06)           | 69/284 (24.30)      | 39/147 (26.53)      |                       |
| > 60                                        | 105/431 (24.36)           | 42/284 (14.79)      | 63/147 (42.86)      |                       |
| Province–no./total no. (%)                  |                           |                     |                     | <0.001*                |
| Hubei                                       | 169/432 (39.12)           | 73/285 (25.61)      | 96/147 (65.31)      |                       |
| Sichuan                                     | 162/432 (37.50)           | 144/285 (50.53)     | 18/147 (12.24)      |                       |
| Chongqing                                   | 38/432 (8.80)             | 29/285 (10.18)      | 9/147 (6.12)        |                       |
| Henan                                       | 30/432 (6.94)             | 15/285 (5.26)       | 15/147 (10.20)      |                       |
| Guizhou                                     | 24/432 (5.56)             | 17/285 (5.96)       | 7/147 (4.76)        |                       |
| Other                                       | 9/432 (2.08)              | 7/285 (2.46)        | 2/147 (1.36)        |                       |
| Ethnicity–no./total no. (%)                 |                           |                     |                     | <0.001*                |
| Han                                         | 360/432 (83.33)           | 220/285 (77.19)     | 140/147 (95.24)     |                       |
| Tibetan                                     | 72/432 (16.67)            | 65/285 (22.81)      | 7/147 (4.76)        |                       |
| Smoking history, yes–no./total no. (%)      | 62/432 (14.35)            | 46/285 (16.14)      | 16/147 (10.88)      | 0.140*                 |
| Pre-existing comorbidity–no./total no. (%)  |                           |                     |                     | <0.001*                |
| None                                        | 300/432 (69.44)           | 226/285 (79.30)     | 74/147 (50.34)      |                       |
| One                                         | 79/432 (18.29)            | 37/285 (12.98)      | 42/147 (28.57)      |                       |
| Multi                                       | 53/432 (12.27)            | 22/285 (7.72)       | 31/147 (21.09)      |                       |
| Symptoms on admission–no./total no. (%)     |                           |                     |                     |                       |
| Fever                                       | 249/432 (57.64)           | 125/285 (43.86)     | 124/147 (84.35)     | <0.001*                |
| Cough                                       | 257/432 (59.49)           | 139/285 (48.77)     | 118/147 (80.27)     | <0.001*                |
| Fatigue                                     | 153/432 (35.42)           | 70/285 (24.56)      | 83/147 (56.46)      | <0.001*                |
| Pain                                        | 68/432 (15.74)            | 40/285 (14.04)      | 28/147 (19.05)      | 0.175*                 |
| Diarrhea                                    | 46/432 (10.65)            | 24/285 (8.42)       | 22/147 (14.97)      | 0.037*                 |
| Bilateral infection scope–no./total no. (%) | 362/432 (83.80)           | 221/285 (77.54)     | 141/147 (95.92)     | <0.001*                |
| Length of hospital stay–no./total no. (%)   |                           |                     |                     |                       |
| Median (IQR) in days                        | 18 (12–25)                | 15 (11–22)          | 23 (15.5–31.61)     | <0.001‡                |
| Distribution–no./total no. (%)              |                           |                     |                     | <0.001*                |
| 1–14 days                                   | 160/408 (39.22)           | 130/268 (48.51)     | 30/140 (21.43)      |                       |
| >14 days                                    | 248/408 (60.78)           | 138/268 (51.49)     | 110/140 (78.57)     |                       |
| Discharge Destination–no./total no. (%)     |                           |                     |                     | <0.001*                |
| Discharged home                             | 278/412 (67.48)           | 215/269 (79.93)     | 63/143 (44.06)      |                       |
| Discharged to 14-day quarantine             | 128/412 (31.07)           | 52/269 (19.33)      | 76/143 (53.15)      |                       |
| Referred to other hospital                  | 6/412 (1.46)              | 2/269 (0.74)        | 4/143 (2.80)        |                       |
| Mechanical Ventilation–no./total no. (%)    |                           |                     |                     | <0.001*                |
| No                                          | 395/411 (96.11)           | 268/268 (100.00)    | 127/143 (88.81)     |                       |
| Yes                                         | 16/411 (3.89)             | 0/268 (0.00)        | 16/143 (11.19)      |                       |
| II. Outcomes (95% CI)                       |                           |                     |                     |                       |
| Disability, percent                         |                           |                     |                     |                       |
| One or more IADL limitations                | 36.81 (32.39–41.46)       | 18.25 (14.18–23.16) | 72.79 (65.04–79.37) | <0.001*                |
| Moderate ADL dependence                     | 16.44 (13.23–20.23)       | 6.32 (4.01–9.80)    | 36.05 (28.71–44.11) | <0.001*                |

(Continued)
Results on risk factors for disability and anxiety are displayed in Figs 1 and 2 (for detailed estimates see S1-S3 Tables in S1 Appendix). Risk ratios for reporting at least one IADL limitation (Fig 1, upper panel) were increased in the older age groups, particularly in survivors aged older than 60 years (adjusted RR 2.518, 95% CI 1.800–3.525), in patients from Hubei (adjusted RR 2.582, 95% CI 1.810–3.684), and in survivors with severe Covid-19 (adjusted RR 2.476, 95% CI 1.801–3.404). The adjusted model also showed an elevated relative risk in survivors from the Tibetan ethnic group (adjusted RR 2.391, 95% CI 1.513–3.780). Only in unadjusted models was the relative risk of having one or more IADL limitations clearly elevated in survivors with comorbidities (unadjusted RR for one comorbidity 2.211, 95% CI 1.694–2.886, unadjusted RR for multi-comorbidity 2.436, 95% CI 1.847–3.212), in patients with more symptoms at admission (unadjusted RR 1.602 95% CI 1.217–2.110), and in those with bilateral infections (unadjusted RR 2.172, 95% CI 1.308–3.605). Both in unadjusted and adjusted models, the relative risk of ADL dependence (Fig 1 lower panel) was consistently increased in Covid-19 survivors aged older than 60 years (adjusted RR 6.783, 95% CI 3.155–14.586), and in participants with severe disease course (adjusted RR 2.074, 95% CI 1.146–3.755) and more symptoms (adjusted RR 2.074, 95% CI 1.129–3.810). All individual risk ratios were higher in unadjusted models. Setting (unadjusted RR 3.048, 95% CI 1.938–4.792), comorbidity (unadjusted RR for one comorbidity 2.211, 95% CI 1.694–2.886, unadjusted RR for multi-comorbidity 2.436, 95% CI 1.847–3.212), symptoms (unadjusted RR 2.303, 95% CI 1.600–3.605) and scope of pneumonia (unadjusted RR 3.232, 95% CI 1.574–6.635) played a role in unadjusted analysis only.

Having severe Covid-19 (adjusted RR 2.533, 95% CI 1.693–3.788) was the strongest risk factor for probable clinically relevant anxiety (Fig 2), followed by having received treatment in Hubei province (adjusted RR 2.055, 95% CI 1.422–2.972). In turn, belonging to the Tibetan group was associated with a largely decreased relative risk of anxiety (adjusted RR 0.214, 95% CI 0.050–0.916). There was a trend for an increased relative risk of anxiety in survivors who had stayed in the hospital for more than 14 days (adjusted RR 1.482, 95% CI 0.998–2.200). Older age (unadjusted RR for being older than 60 2.318, 95% CI 1.650–3.255), comorbidity (unadjusted RR for one comorbidity 1.899, 95% CI 1.345–2.681; unadjusted RR for multi-comorbidity 2.476, 95% CI 1.772–3.462), symptoms (unadjusted RR 2.303, 95% CI 1.600–3.315), and scope of pneumonia (unadjusted RR 3.232, 95% CI 1.574–6.635) played a role in unadjusted analysis only.

Table 1. (Continued)

| I. Demographic and clinical characteristics | All participants (N = 432) | By disease severity |
|--------------------------------------------|--------------------------|-------------------|
|                                            | non-severe (n = 285, 65.97%) | severe (n = 147, 34.03%) | P |
| Severe ADL dependence                      | 5.56 (3.75–8.15)         | 2.46 (1.17–5.06) | 11.56 (7.31–17.82) | <0.001* |
| Anxiety, percent (95% CI)                  | 28.70 (24.63–33.15)      | 13.33 (9.86–17.80) | 58.50 (50.38–66.19) | <0.001* |

*Scope of pneumonia as confirmed by radiography.
*For 24 (5.56%) patients discharge date had not been entered in the data form.
*P-values from chi-squared test.
*P-values from Mann-Whitney U test.
*Confidence intervals and p-values estimated from logistic regression.
CI = confidence interval. IADL = instrumental activities of daily living. ADL = activities of daily living.
Fig 1. Disability (IADL limitations and ADL dependence) in relation to potential risk factors. Risk ratios and 95% confidence intervals. Estimated from log-linear Poisson regression with robust standard errors; unadjusted risk ratios are estimated from univariable models for the effect of the respective predictor on the outcome, adjusted risk ratios are estimated from a multivariable model containing all potential risk factors. IADL = Instrumental Activities of Daily Living. ADL = Activities of Daily Living. CI = confidence interval. Note: In the case of ADL dependence, the upper limit of the confidence interval for the unadjusted estimate of age > 60 years has been truncated for better readability of the other effects (see S1-S3 Tables in S1 Appendix for details). Adjusted model and unadjusted model for age have been estimated for 431 cases (because of one missing date of birth).

https://doi.org/10.1371/journal.pone.0243883.g001
Table 2 show the results of the ZIP regression of the number of IADL limitations on risk factors. Hospitalization in Hubei, Tibetan ethnicity (IRR 0.16, 95% CI 0.06–0.41), and multi-comorbidity (IRR 0.33, 95% CI 0.12–0.90) were associated with lower odds of having a zero count of IADL limitations. For all age groups, odds for having zero IADL limitations were decreased in people with severe Covid-19. This effect became however smaller with increasing age. IRRs were 0.06 (95% CI 0.02–0.17) for the youngest age group with severe Covid-19, 0.11 (95% CI 0.04–0.32) for the middle age group, and 0.34 (95% CI 0.10–1.16) for the oldest participants with severe Covid-19 as compared to those with non-severe disease. Disease severity (IRR 1.64, 95% CI 0.97–2.80), its interaction with age (see Table 2 for detailed estimates), and symptoms (IRR 1.34, 95% CI 1.10–1.62) were associated with a greater number of health problems. The joint effect of age and degree of severity of Covid-19 on the number of IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups having a severe course of Covid-19 was associated with a higher number of self-reported IADL limitations. Point estimates for survivors with non-severe and those with severe disease were however closer in the oldest age group. CIs for the number of IADL limitations in participants with non-severe and those with severe Covid-19 moved closer in both older age groups and overlapped in survivors aged 61 years and older.

Fig 2. Probable clinical anxiety in relation to potential risk factors. Risk Ratios and 95% confidence intervals. Estimated from log-linear Poisson Regression with robust standard errors; unadjusted risk ratios are estimated from univariable models for the effect of the respective predictor on the outcome, adjusted risk ratios are estimated from a multivariable model containing all potential risk factors. The adjusted model has been estimated for 407 cases (because of missing information regarding length of stay for 24 cases and one case with missing date of birth). Unadjusted model estimated for 407 cases (because of missing information regarding length of stay for 24 cases and one case with missing date of birth). CI = confidence interval.

https://doi.org/10.1371/journal.pone.0243883.g002

Effects of risk factors on the number of limitations in IADL

Table 2 show the results of the ZIP regression of the number of IADL limitations on risk factors. Hospitalization in Hubei, Tibetan ethnicity (IRR 0.16, 95% CI 0.06–0.41), and multi-comorbidity (IRR 0.33, 95% CI 0.12–0.90) were associated with lower odds of having a zero count of IADL limitations. For all age groups, odds for having zero IADL limitations were decreased in people with severe Covid-19. This effect became however smaller with increasing age. IRRs were 0.06 (95% CI 0.02–0.17) for the youngest age group with severe Covid-19, 0.11 (95% CI 0.04–0.32) for the middle age group, and 0.34 (95% CI 0.10–1.16) for the oldest participants with severe Covid-19 as compared to those with non-severe disease. Disease severity (IRR 1.64, 95% CI 0.97–2.80), its interaction with age (see Table 2 for detailed estimates), and symptoms (IRR 1.34, 95% CI 1.10–1.62) were associated with a greater number of health problems. The joint effect of age and degree of severity of Covid-19 on the number of IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups having a severe course of Covid-19 was associated with a higher number of self-reported IADL limitations. Point estimates for survivors with non-severe and those with severe disease were however closer in the oldest age group. CIs for the number of IADL limitations in participants with non-severe and those with severe Covid-19 moved closer in both older age groups and overlapped in survivors aged 61 years and older.
Discussion

This retrospective cohort study found a considerable prevalence of functional limitations and dependence as well as anxiety in Covid-19 survivors at about time of discharge from acute
inpatient treatment. Disease severity was a major independent risk factor for all outcomes. Age was an additional risk factor for both disability outcomes, and setting (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a strong protective factor for anxiety but a risk factor for IADL limitations when it was adjusted for covariates.

Demographic and clinical characteristics of the study population were comparable to other reports on Covid-19 patients from China [1, 3] with two exceptions: a higher percentage was classified as severe cases and current smoking was more prevalent in the non-severe disease group. An explanation for the higher percentage of severe cases in the present study is that the applied criteria for classifying Covid-19 cases as severe by the National Health Commission of the PR China are more liberal than the criteria for severe community-acquired pneumonia by the American Thoracic Society and Infectious Disease Society of America [22] used by Guan et al. [3]. The lower prevalence of smokers in participants with severe disease was unexpected and contradicts previous evidence in this regard [3]. A possible explanation is that current smoking status was self-reported and participants with more severe disease outcomes did not reveal their true smoking status, perhaps for fear of being stigmatized and held responsible for contracting SARS CoV-2 or the severity of Covid-19.

We found a high prevalence of disability and anxiety, particularly in severe cases. Almost three quarters of severe Covid-19 survivors experienced at least one IADL problem and more than one third had at least moderate ADL dependence. The six percent of the overall sample with severe ADL dependence are of particular concern since severe functional dependence has been a reliable predictor of mortality in populations with other health conditions [23]. We
found moderate to strong associations between outcomes, alluding to possible processes of mediation, i.e. indirect effects on one outcome triggered by the other outcomes. No other original study directly investigated disability outcomes related to Covid-19 so far. Follow up studies of SARS and Middle East Respiratory Syndrome (MERS) survivors have however shown that decreased exercise capacity and distance walked, fatigue, sleeping problems, shortness of breath, reduced self-rated health, work disability, and structural damage (e.g. osteonecrosis) from corticosteroids were prevalent in survivors even years after onset of symptoms [11, 24, 25]. In addition, access to health care, quality of services, and employment opportunities of former SARS patients were compromised by enduring stigma [13, 26]. Our findings imply that a large proportion of Covid-19 survivors, particularly those who experienced severe disease episodes are in need of follow up care and rehabilitation services. This proportion may be reduced by the integration of early rehabilitation interventions into acute care [27, 28].

Probable clinical anxiety disorder was found in one third of the overall sample and its prevalence was almost four-fold increased in severe as compared to non-severe cases. Previous studies on mental health in the Covid-19 pandemic have been conducted in the general population [29, 30] and health professionals [31] but not in the patient population. Studies in SARS survivors have however reported highly elevated long-term psychiatric morbidity [32] and demonstrated adverse effects on the mental health of caregivers [11]. Our findings point to the need of psychological counseling during acute care and mental health follow-up in many Covid-19 survivors to mitigate suffering and prevent the manifestation of psychiatric disorders.

Major risk factors for mortality due to Covid-19 [1, 33] were also major risk factors of disability: older age and severe disease course both independently increased the relative risk of IADL limitations and ADL dependence. However, comorbidity [34] had an adverse effect on disability outcomes in unadjusted analysis only. Though attenuated, disease severity continued to play a major role when it was adjusted for age, co-morbidity, and other potential confounders demonstrating an additional effect of Covid-19 when other known risk factors for disability were held statistically constant. In all age groups having severe Covid-19 was associated with a higher number of self-reported IADL limitations. For survivors aged over 60 years we found that the extent of IADL limitations was more similar in those with non-severe and severe Covid-19 than in the other age groups. Accordingly, the oldest participants with non-severe Covid-19 were more similar to survivors with severe disease in the younger age groups. There are two possible explanations for this phenomenon that deserve further scrutiny: First, older people have already more activity limitations before they acquire Covid-19. Second, a non-severe disease course has a greater effect on IADL limitations for them. Persistence of this effect when it was adjusted for comorbidity speaks for the latter explanation. Having been treated in hospitals of Hubei province where Covid-19 spread first and overwhelmed an unprepared health system was furthermore associated with adverse disability outcomes, particularly IADL limitations. Moreover, belonging to the Tibetan ethnic minority predicted worse IADL outcomes when it was controlled for other potential risk factors. Given that the Tibetan population of Sichuan province mainly lives in rural, mountainous areas, both findings point at the role that environmental factors including the availability and accessibility of targeted services play in the disablement process [35]. Our findings indicate that priority in rehabilitation resource allocation should be given to patients with severe disease course, older people, and those living in environments with restricted accessibility of services.

Regarding anxiety, outstanding independent risk factors were severity of Covid-19 and setting, i.e. having been hospitalized in Hubei province. Apart from the specific situation in hospitals in Hubei, insecurity about causes, transmission patterns, and prognosis when Covid-19 first occurred likely contributed to this finding. Moreover, we found a trend for longer length
of hospital stay being independently associated with increased relative risk of anxiety. In contrast to disability outcomes, Tibetan ethnicity was a consistent protective factor in unadjusted as well as adjusted models of anxiety. Possible explanations are cultural factors including larger families (due to the non-application of China’s one child policy to this group) and greater social cohesion and support. This finding needs further exploration. Our results point towards heightened need for psychological support in patients who experienced severe disease episodes and people from areas hardest hit by the Covid-19 pandemic [36, 37].

Study limitations
The present study has limitations. First, baseline data for the outcomes analyzed here were not available. Because of this, we cannot rule out that patients had disability or anxiety before they contracted Covid-19, indeed having disability may have made people more vulnerable to the disease [38–40]. However, most patients first presented already with severe symptoms and baseline information collected before admission is rare in any disease. Baseline information on comorbidity is thus as close as we get to baseline disability and the effects of disease severity on outcomes remained consistent when adjusted for baseline comorbidity in our analysis. Second, we may be criticized for not having employed some kind of control group. An appropriate control group for the effects and population under investigation is however difficult to define and to establish. Age and gender matched general population controls are surely not appropriate because of the lack of hospitalization. Investigating patients who have been hospitalized for some other disease would not help disentangle the effects of disease and hospitalization. Quarantined persons suspected for Covid-19 or those treated at home may make up an interesting comparator but are difficult to access. We believe that our comparison of patients with severe and non-severe Covid-19 nonetheless provides initial evidence for the potential impact of the disease on function and mental health, and is an important starting point in investigating this population’s rehabilitation needs. Third, outcome data were self-reported by patients due to the lack of options for objective measurement. Survivors thus may have under- or overestimated their physical abilities. Patient-reported outcome measures have however not been used in this population before to the best of our knowledge, making it difficult to appraise if and to what degree this kind of problem existed. Fourth, psychiatric confirmation of anxiety in those screened positive was not possible. Fifth, outcomes were correlated with each other pointing at possible mediation of effects. Indirect effects due to mediation were however not formally examined here given the cross-sectional nature of outcome assessment. Furthermore, we refrained from more complex analyses due to the novel character of the presented data and the therefore exploratory character of analysis. Sixth, this study evaluated outcomes at discharge and conclusions about longer-term prevalence, spontaneous recovery, and chronic manifestations cannot be drawn at this point and further follow-up of the cohort is therefore indicated.

Recommendations
In spite of these limitations, there are several recommendations that can be derived from our findings. First, awareness about possible functional and psychological consequences of Covid-19 needs to be raised in patients, care providers, and health policy makers [28]. Second, early psychological [41] and pulmonary rehabilitation interventions including mobilization and exercise [27, 28, 42] which have been investigated in other health conditions could be effective and important to meet therapeutic windows; consequently their application (besides pharmacological treatments) needs to be studied in the population of Covid-19 patients, particularly those with severe disease. Third, this involves a better integration of primary care and psychiatric and rehabilitation services which is unfortunately lacking in many lower as well as higher
resourced countries including China [43]. Fourth, systematic community follow up and two-way referral systems between community health centers and specialized hospital units, another weak point of many health systems, need to be strengthened [43]. Fifth, we recommend that future prospective cohort studies in Covid-19 survivors include functional and psychiatric outcomes.

**Conclusion**

A significant proportion of Covid-19 survivors had disability and anxiety at discharge from hospital. Disease severity was the only independent risk factor with consistent adverse effects on all outcomes. Health systems need to be prepared for an additional long-term burden due to Covid-19. This includes raising awareness about mental and physical health problems of survivors, early interventions, strengthening medical follow up, and increasing physical and psychological rehabilitation capacity.

**Supporting information**

S1 Appendix. Estimates of risk ratios and 95% confidence intervals from log-linear Poisson regression with robust standard errors.

(DOCX)

S1 Checklist. STROBE statement—Checklist of items that should be included in reports of observational studies.

(DOCX)

**Acknowledgments**

We thank all the hospital staff members and coordinators under the CSPRM Covid-19 network for their efforts in collecting the information that was used in this study; Liangjiang Huang (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology), Xu Qin (No.3 People’s Hospital of Chengdu), Mingqing Li (Dazhou Central Hospital), Kehui Hu (Suining Central Hospital), and Jinling Zhang (West China Second University Hospital, Sichuan University) for their dedication to data entry and verification; Prof. Deying Kang (Epidemiologist, West China Hospital, Sichuan University) and Mrs. Rouyue Fang (Statistician, Industrial and Commercial Bank of China) for their assistance in initial data extraction and processing; all the patients who consented to provide their data for analysis and the medical staff members who are at the frontline caring for patients with Covid-19. We would like to thank Prof. Dr. Gerold Stucki and Cristiana Baffone for constructive comments on an earlier version of the manuscript.

**Author Contributions**

**Conceptualization:** Siyi Zhu, Qiang Gao, Lin Yang, Wenguang Xia, Chunping Du, Chengqi He, Jan D. Reinhardt.

**Data curation:** Siyi Zhu, Qiang Gao, Lin Yang, Yonghong Yang, Wenguang Xia, Yanping Hui, Chunping Du, Hongchen He, Yun Qu, Chengqi He, Jan D. Reinhardt.

**Formal analysis:** Siyi Zhu, Qiang Gao, Lin Yang, Yonghong Yang, Wenguang Xia, Hongchen He, Yun Qu, Chengqi He, Jan D. Reinhardt.

**Funding acquisition:** Siyi Zhu, Chengqi He, Jan D. Reinhardt.
Investigation: Siyi Zhu, Qiang Gao, Lin Yang, Yonghong Yang, Xiguo Cai, Yanping Hui, Di Zhu, Yanyan Zhang, Guiqing Zhang, Shuang Wu, Yiliang Wang, Zhiqiang Zhou, Hongfei Liu, Changjie Zhang, Bo Zhang, Jianrong Yang, Mei Feng, Baoyu Chen, Chunping Du, Hongchen He, Quan Wei, Chengqi He, Jan D. Reinhardt.

Methodology: Siyi Zhu, Qiang Gao, Lin Yang, Quan Wei, Chengqi He, Jan D. Reinhardt.

Project administration: Siyi Zhu, Yonghong Yang, Wenguang Xia, Xiguo Cai, Di Zhu, Shuang Wu, Mei Feng, Chengqi He, Jan D. Reinhardt.

Resources: Siyi Zhu, Lin Yang, Yonghong Yang, Xiguo Cai, Yanping Hui, Di Zhu, Yanyan Zhang, Guiqing Zhang, Shuang Wu, Yiliang Wang, Zhiqiang Zhou, Hongfei Liu, Changjie Zhang, Bo Zhang, Jianrong Yang, Mei Feng, Zhong Ni, Baoyu Chen, Chunping Du, Hongchen He, Chengqi He, Jan D. Reinhardt.

Software: Siyi Zhu, Jan D. Reinhardt.

Supervision: Siyi Zhu, Yonghong Yang, Yun Qu, Quan Wei, Chengqi He, Jan D. Reinhardt.

Validation: Siyi Zhu, Qiang Gao, Lin Yang, Yonghong Yang, Xiguo Cai, Yanyan Zhang, Zhong Ni, Yun Qu, Chengqi He, Jan D. Reinhardt.

Visualization: Siyi Zhu, Yonghong Yang, Yanping Hui, Yanyan Zhang, Jan D. Reinhardt.

Writing – original draft: Siyi Zhu, Qiang Gao, Yonghong Yang, Yanping Hui, Hongchen He, Chengqi He, Jan D. Reinhardt.

Writing – review & editing: Siyi Zhu, Qiang Gao, Lin Yang, Wenguang Xia, Xiguo Cai, Yanping Hui, Di Zhu, Yanyan Zhang, Guiqing Zhang, Shuang Wu, Yiliang Wang, Zhiqiang Zhou, Hongfei Liu, Changjie Zhang, Bo Zhang, Jianrong Yang, Mei Feng, Zhong Ni, Baoyu Chen, Chunping Du, Yun Qu, Quan Wei, Chengqi He, Jan D. Reinhardt.

References

1. Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. European Respiratory Journal. 2020; 55(6).

2. Center for Evidence Based Medicine (CEBM). Global Covid-19 Case Fatality Rates (last updated on June 6 2020) 2020 [cited 2020 Aug 10]. https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/.

3. Guan W-j, Li Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020. Epub 2020/02/29. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013.

4. Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. Journal of global infectious diseases. 2017; 9(4):151–6. Epub 2018/01/06. https://doi.org/10.4103/jgid.jgid_66_17 PMID: 29302150.

5. Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care. 2013; 17(3):R100. Epub 2013/05/30. https://doi.org/10.1186/cc12745 PMID: 23714892.

6. Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017; 358:j2471. Epub 2017/07/12. https://doi.org/10.1136/bmj.j2471 PMID: 28694251.

7. Fraser E. Long term respiratory complications of covid-19. British Medical Journal Publishing Group; 2020.

8. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments. European journal of epidemiology. 2020; 35(4):335. https://doi.org/10.1007/s10654-020-00628-1 PMID: 32296994
9. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159):1789–858.

10. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159):1859–922.

11. Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Archives of internal medicine. 2007; 167(12):1312–20. https://doi.org/10.1001/archinte.167.12.1312 PMID: 17592106

12. Zung WW. A Rating Instrument For Anxiety Disorders. Psychosomatics. 1971; 12(6):371–9. https://doi.org/10.1016/S0033-3182(71)71479-0 PMID: 5172928

13. Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge: a study of Hong Kong Chinese version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR: Occupation, Participation and Health. 2002; 22(4):132–42.

14. National Health Commission of the PR China [国家卫生健康委员会]. Diagnostic criteria of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) [在：有关印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知2020]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cebbd89cd75912e9d98.shtml.

15. Tong AY, Man DW. The validation of the Hong Kong Chinese version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR: Occupation, Participation and Health. 2002; 22(4):132–42.

16. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and prognosis. Journal of neurology, neurosurgery, and psychiatry. 1987; 50(2):177–82. Epub 1987/02/01. https://doi.org/10.1136/jnnp.50.2.177 PMID: 3572432

17. Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge: a study of Hong Kong Chinese version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR: Occupation, Participation and Health. 2002; 22(4):132–42.

18. Zung WW. A Rating Instrument For Anxiety Disorders. Psychosomatics. 1971; 12(6):371–9. https://doi.org/10.1016/S0033-3182(71)71479-0 PMID: 5172928

19. Dunstan DA, Scott N. Norms for Zung’s Self-rating Anxiety Scale. BMC psychiatry. 2020; 20(1):90. Epub 2020/05/03. https://doi.org/10.1186/s12888-019-2427-6 PMID: 32111187.

20. Cohen J. Statistical Power Analysis Jbr the Behavioral. Sciences Hillsdale (NJ): Lawrence Erlbaum Associates. 1988:18–74.

21. Zou G. A modified poisson regression approach to prospective studies with binary data. American journal of epidemiology. 2004; 159(7):702–6. https://doi.org/10.1093/aje/kwh090 PMID: 15033648

22. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine. 2019; 200(7):e45–e67. Epub 2019/10/02. https://doi.org/10.1164/rccm.201908-1518ST PMID: 31573350.

23. Alger HM, Williams JH Iv, Walchok BJ, Bolles MM, Fonnarow GC, Rutan C. The Role of Data Registries in the Time of COVID-19. Circulation Cardiovascular quality and outcomes. 2020. Epub 2020/04/17. https://doi.org/10.1161/CIRCOUTCOMES.120.006766 PMID: 32298145.

24. Cao W-C, De Vlas SJ, Richards JH. The severe acute respiratory syndrome epidemic in mainland China dissected. Infectious disease reports. 2011; 3(1). https://doi.org/10.4081/idr.2011.e2 PMID: 24470901

25. Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindl A, Johni SA, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health and quality of life outcomes. 2019; 17(1):101. https://doi.org/10.1186/s12955-019-1165-2 PMID: 31186042

26. Lee S, Chan LY, Chau AM, Kwok KP, Kleinman A. The experience of SARS-related stigma at Amoy Gardens. Soc Sci Med. 2005; 61(9):2038–46. Epub 2005/05/26. https://doi.org/10.1016/j.socscimed.2005.04.016 PMID: 15913861.

27. Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC pulmonary medicine. 2018; 18(1):154. Epub 2018/09/17. https://doi.org/10.1186/s12890-018-0719-1 PMID: 30219047.
28. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. The European respiratory journal. 2016; 47(5):1336–41. Epub 2016/05/02. https://doi.org/10.1183/13993003.02151-2015 PMID: 27132269.

29. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerging Microbes and Infections. 2020; 9(1):313–9. https://doi.org/10.1080/22221751.2020.1725399 PMID: 32020836.

30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507–13. Epub 2020/02/03. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32007143.

31. Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA network open. 2020; 3(3):e203976. Epub 2020/03/24. https://doi.org/10.1001/jamanetworkopen.2020.3976 PMID: 32202646.

32. Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among SARS survivors. General hospital psychiatry. 2009; 31(4):318–26. https://doi.org/10.1016/j.genhosppsych.2009.03.001 PMID: 19555791

33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–62. Epub 2020/03/15. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076.

34. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal. 2020; 55(5). https://doi.org/10.1183/13993003.00547-2020 PMID: 32217650

35. WHO. International Classification of Functioning, Disability, and Health. Geneva: WHO Press; 2001.

36. Bishop GD, Kaur D, Tan VL, Chua Y-L, Liew S-M, Mak K-H. Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting. 2005.

37. Li C, Chu F, Wang H, Wang Xp. Efficacy of Williams Life Skills training for improving psychological health: A pilot comparison study of Chinese medical students. Asia-Pacific Psychiatry. 2014; 6(2):161-9. https://doi.org/10.1111/appy.12084 PMID: 23857943

38. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet Public Health. 2020; 5(5):e257. https://doi.org/10.1016/S2468-2667(20)30076-1 PMID: 32224295

39. WHO. Disability considerations during the COVID-19 outbreak: World Health Organization; 2020 [cited 2020 Aug 10]. https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-eng.pdf.

40. Solomon MZ, Wynia MK, Gostin LO. Covid-19 crisis triage—optimizing health outcomes and disability rights. New England Journal of Medicine. 2020. https://doi.org/10.1056/NEJMp2008300 PMID: 32427434

41. Giummarrz MJ, Lennox A, Dali G, Costa B, Gabbe BJ. Early psychological interventions for posttraumatic stress, depression and anxiety after traumatic injury: A systematic review and meta-analysis. Clinical psychology review. 2018; 62:11–36. Epub 2018/05/14. https://doi.org/10.1016/j.cpr.2018.05.001 PMID: 29754102.

42. Zhang L, Hu W, Cai Z, Liu J, Wu J, Deng Y, et al. Early mobilization of critically ill patients in the intensive care unit: A systematic review and meta-analysis. PLoS One. 2019; 14(10):e0223185. Epub 2019/10/04. https://doi.org/10.1371/journal.pone.0223185 PMID: 31581205.

43. Xiao Y, Zhao K, Ma ZX, Li X, Qiu YP. Integrated medical rehabilitation delivery in China. Chronic diseases and translational medicine. 2017; 3(2):75–81. Epub 2017/10/25. https://doi.org/10.1016/j.cdtm.2017.02.003 PMID: 29063059.